Bosh sahifaIMMP • NASDAQ
add
Immutep Ltd - ADR
1,93 $
Seans yopilganidan keyin:(0,26%)-0,0050
1,92 $
Yopilgan:22-noy, 19:02:12 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
1,84 $
Kunlik diapazon
1,87 $ - 1,96 $
Yillik diapazon
1,66 $ - 3,34 $
Bozor kapitalizatsiyasi
282,04 mln USD
Oʻrtacha hajm
101,17 ming
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (AUD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 865,57 ming | -4,89% |
Joriy xarajat | 2,03 mln | -10,92% |
Sof foyda | -10,74 mln | -11,49% |
Sof foyda marjasi | -1,24 ming | -17,23% |
Har bir ulushga tushum | — | — |
EBITDA | -11,21 mln | -17,52% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (AUD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 181,88 mln | 47,37% |
Jami aktivlari | 201,58 mln | 36,71% |
Jami passivlari | 12,06 mln | 9,82% |
Umumiy kapital | 189,52 mln | — |
Tarqatilgan aksiyalar | 1,45 mlrd | — |
Narxi/balansdagi bahosi | 14,15 | — |
Aktivlardan daromad | -14,53% | — |
Kapitaldan daromad | -15,32% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (AUD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -10,74 mln | -11,49% |
Operatsiyalardan naqd pul | -8,19 mln | 30,16% |
Sarmoyadan naqd pul | -10,30 mln | -87 445,92% |
Moliyadan naqd pul | 47,81 mln | 25,58% |
Naqd pulning sof oʻzgarishi | 29,03 mln | 5,47% |
Boʻsh pul | -6,10 mln | -44,31% |
Haqida
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Tashkil etilgan
2001
Sayt
Xodimlar soni
19
